Amarin Corp plc (ADR) (NASDAQ:AMRN)

CAPS Rating: 3 out of 5

The Company is engaged in the research, development and commercialization of novel drugs for the treatment of central nervous system disorders.

AMRN News and Commentary

Caps

How do you think AMRN will perform against the market?

Add Stock to CAPS Watchlist

All Players

307 Outperform
27 Underperform
 

All-Star Players

33 Outperform
7 Underperform
 

Wall Street

1 Outperform
1 Underperform
 

Top AMRN Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Rilac (92.30)
Submitted October 11, 2013

after perusing the brief documents for the adcom on the 16th, it seems as if the price movement for Amarin has been over exaggerated. i read nothing really abhorrent. nonetheless i took in a position before today's closing

chris293 (64.22)
Submitted May 07, 2013

FDA approval for fish oil? What else is going on here, are they selling the good parts of the company for what?

AMRN VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about AMRN.

Recs

0
Member Avatar TMFEBCapital (88.78) Submitted: 7/12/2018 11:50:52 AM : Outperform Start Price: $2.96 AMRN Score: -3.51

This is a high-risk stock with a binary event fast-approaching. Management plans to report cardiovascular outcomes data for Vascepa by the end of the quarter and if the results are good, then it could significantly boost sales. A failure, however, would be devastating. This is definitely a buyer-beware kind of stock not for the faint of heart.

Recs

0
Member Avatar westpointe3 (< 20) Submitted: 2/14/2018 6:51:43 AM : Outperform Start Price: $3.51 AMRN Score: -24.24

With the expected good news coming from the Reduce-It study due out, I think the price could go well past 10/share.

Recs

0
Member Avatar Reydad92 (< 20) Submitted: 1/5/2018 4:53:59 AM : Outperform Start Price: $4.36 AMRN Score: -37.04

Superb scientific team behind the science. Company resilience. (First Pharm company to ever sue and win against the FDA for the right to promote its pharmaceutical principle.) Steadily improving financials. Recent results from other lipid lowering drugs that do not target triglycerides have spun up major interest in reducing "Residual Risk". Exactly what Vascepa aims to do. Huge market opportunity

Leaderboard

Find the members with the highest scoring picks in AMRN.

Score Leader

TrackWedbush

TrackWedbush (87.65) Score: +381.18

The Score Leader is the player with the highest score across all their picks in AMRN.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
smoaky < 20 3/28/2007 Underperform 5Y $21.80 -86.70% +109.46% +196.16 0 Comment
MaxPwr273 68.62 10/26/2011 Underperform 5Y $9.33 -69.13% +126.24% +195.38 0 Comment
bwlink100 39.04 4/13/2007 Underperform 1Y $29.60 -90.20% +104.96% +195.17 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. Lolly131313 92.47 4/19/2007 Underperform 3Y $37.50 -92.27% +101.94% +194.20 0 Comment
zeccoscott < 20 4/20/2007 Underperform 3W $39.20 -92.60% +100.35% +192.95 0 Comment
littlejoyusone 60.88 4/20/2007 Underperform 3W $39.20 -92.60% +100.35% +192.95 0 Comment
Luisaespinoza7 < 20 5/18/2012 Underperform 3M $10.34 -72.15% +113.86% +186.01 0 Comment
H8CAGERS < 20 12/1/2011 Underperform 1Y $7.31 -60.60% +124.98% +185.58 0 Comment
Okcfirefighter < 20 12/17/2010 Underperform 5Y $6.72 -57.14% +125.93% +183.08 0 Comment
HedgeFund007 91.07 12/6/2010 Underperform 1Y $5.50 -47.64% +129.10% +176.74 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackJimCramer 85.67 1/3/2013 Underperform 3W $8.38 -65.63% +92.79% +158.42 0 Comment
TrackPoisedTo < 20 12/20/2012 Outperform 5Y $8.42 -65.80% +94.59% -160.39 0 Comment
TrackCitigroup 92.50 4/30/2012 Outperform NS $12.50 -88.32% +35.24% -123.56 5/12/2014 @ $1.46 0 Comment
TrackJimCramer 85.67 3/22/2012 Outperform 3W $11.91 -29.64% +4.69% -34.33 1/3/2013 @ $8.38 0 Comment
TrackMKMPartners 92.95 7/12/2011 Outperform NS $14.24 -84.34% +39.55% -123.89 1/16/2014 @ $2.23 0 Comment
TrackCanaccord 68.89 4/18/2011 Outperform NS $16.51 -87.95% +32.92% -120.87 10/18/2013 @ $1.99 0 Comment
TrackWedbush 87.65 7/20/2010 Outperform NS $2.23 +418.39% +37.21% +381.18 10/3/2012 @ $11.56 0 Comment

Featured Broker Partners


Advertisement